Ultragenyx Pharmaceutical (RARE) Interest Expenses (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Interest Expenses for 14 consecutive years, with $21.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest Expenses rose 50.0% year-over-year to $21.0 million; the TTM figure through Mar 2026 stood at $68.7 million (up 12.27% YoY), while the FY2025 annual figure was $62.0 million, down 1.59% from the prior year.
• Interest Expenses improved to $21.0 million in Q1 2026 per RARE's latest filing, from $19.5 million in the prior quarter.
• Across five years, Interest Expenses topped out at $21.0 million in Q1 2026 and bottomed at $6.6 million in Q1 2022.
• Historically, Interest Expenses has averaged $15.1 million across 5 years, with a median of $15.6 million in 2023.
• On a YoY basis, Interest Expenses climbed as much as 317.3% in 2022 and fell as far as 21.79% in 2022.
• Ultragenyx Pharmaceutical's Interest Expenses stood at $15.9 million in 2022, then gained by 9.13% to $17.3 million in 2023, then decreased by 10.64% to $15.5 million in 2024, then climbed by 25.76% to $19.5 million in 2025, then increased by 7.86% to $21.0 million in 2026.
• Business Quant data shows RARE's Interest Expenses at $21.0 million in Q1 2026, $19.5 million in Q4 2025, and $14.1 million in Q3 2025.